PALO ALTO, Calif.--(BUSINESS WIRE)--Connetics Corporation (NASDAQ: CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, today announced the nationwide U.S. commercial launch of Verdeso™ (desonide) Foam, 0.05%, for the treatment of mild-to-moderate atopic dermatitis in adults and children as young as three months of age. Verdeso, a low-potency topical steroid, is the first commercial product formulated in Connetics’ proprietary VersaFoam-EF™ emulsion formulation foam vehicle, and is the first Connetics product to include a pediatric indication. Verdeso is available in 50g and 100g trade unit sizes.
